BioCentury
ARTICLE | Clinical News

Luspatercept: Preliminary Phase II data

May 11, 2015 7:00 AM UTC

Preliminary data from 44 evaluable patients with low or intermediate-1 risk myelodysplastic syndrome (MDS) in an open-label, German Phase II trial showed that 33% of patients receiving 0.125-0.5 mg/kg...